Products

Solid Tumor Testing Minimal Residual Disease Testing Hematologic Malignancies Testing RUO/IUO: Multi-omics Detection Early Cancer Detection
Services

Pharma Biomarker and CDx Services IVD Channel Partner Development Sequencing Services Early Cancer Detection Services

中文 EN

Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial

Release date：February 19, 2024

Announcer：Burning Rock

Previous: Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE/CTONG2104)

Next: Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Recommended News

August 03, 2024

Development and validation of an integrated system for lungcancer screening and post-screening pulmonary nodulesmanagement: a proof-of-concept study (ASCEND-LUNG)

June 18, 2024

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE/CTONG2104)

February 16, 2024

Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation

January 09, 4218

Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma

Contact Our Experts

We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."